Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Minimal Residual Disease Testing Market Forecast: What Value Will The Market Reach By 2030?
The minimal residual disease testing market has experienced substantial growth in its size recently. This market is forecasted to expand from $1.8 billion in 2025 to $2.02 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 12.5%. Historically, this upward trend can be ascribed to factors like the increasing prevalence of hematological malignancies, advancements in molecular diagnostic technologies, heightened awareness about minimal residual disease, a wider embrace of precision medicine, and supportive government healthcare initiatives.
The minimal residual disease testing market is projected to experience substantial expansion in the coming years, anticipated to reach a valuation of $3.31 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.1%. Factors driving this growth during the forecast period include improvements in technologies such as nGS and digital PCR, increased investment in cancer research, stronger partnerships between diagnostic and pharmaceutical firms, a greater need for individualized treatment oversight, and enhancements in healthcare infrastructure within developing economies. Key trends anticipated for this period encompass the widespread use of liquid biopsy, customized cancer monitoring, advances in early detection and prognosis, the incorporation of molecular diagnostics, and a broader scope of oncology research.
Get A Free Sample Report With In-Depth Market Insights:
Minimal Residual Disease Testing Market Growth Factors Behind Sustained Expansion
The rising incidence of cancer is anticipated to fuel the expansion of the minimal residual disease testing market moving forward. Cancer is defined as a condition where some cells in the body proliferate uncontrollably and disseminate to other areas. Minimal residual disease testing, a highly sensitive technique for identifying cancer cells in the human body, is crucial for detecting cancer stages. This method assists patients in averting the progression of cancer at an early stage, thereby stimulating the minimal residual disease testing market. For example, data from January 2023, released by the National Institutes of Health (NIH), a U.S.-based government body, indicated that the United States was expected to see 1,958,310 new cancer cases and 609,820 cancer deaths in 2023. Consequently, the growing prevalence of cancer is propelling the growth of the minimal residual disease testing market.
Minimal Residual Disease Testing Market Segment Analysis And Revenue Potential
The minimal residual disease testing market covered in this report is segmented –
1) By Test Type: DNA – Based Test, RNA- Based Test, Immunological Test
2) By Technology: Flow Cytometry, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Other Technologies
3) By Application: Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors, Other Application
4) By End User: Hospitals And Specialty Clinics, Diagnostic Laboratories, Academic And Research Institutes, Other End Users
Subsegments:
1) By DNA-Based Test: Polymerase Chain Reaction (PCR) Tests, Next-Generation Sequencing (NGS), Digital PCR
2) By RNA-Based Test: Reverse Transcription PCR (RT-PCR), RNA Sequencing, Quantitative PCR (qPCR)
3) By Immunological Test: Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry
Minimal Residual Disease Testing Market Industry Trends Fueling Future Revenue Growth
Leading companies in the minimal residual disease testing market are introducing cancer research testing solutions to enhance detection sensitivity, improve treatment monitoring, and advance precision medicine approaches for better patient outcomes. The IDT Archer FUSIONPlex Core Solid Tumor Panel refers to a targeted next-generation sequencing assay utilized for identifying gene fusions and mutations in solid tumors, aiding in precision oncology and treatment decision-making. For instance, in April 2023, Integrated DNA Technologies (IDT), a US-based provider of genomic solutions, launched the IDT Archer FUSIONPlex Core Solid Tumor Panel, an enhanced cancer research testing solution, now offering expanded and optimized coverage for single nucleotide variants (SNVs) and indels. This RNA-based sequencing assay simplifies fusion detection and variant calling in solid tumors, using a single sample input and providing researchers with a scalable, user-friendly solution that conserves time, resources, and costs.
Minimal Residual Disease Testing Market Key Players Shaping Industry Direction
Major companies operating in the minimal residual disease testing market are Natera Inc., Guardant Health Inc., Laboratory Corporation of America Holdings, QIAGEN NV, F. Hoffmann-La Roche Ltd., Bio-Techne Corporation, Bio-Rad Laboratories Inc., Sysmex Corporation, Exact Sciences Corporation, GRAIL LLC, Veracyte Inc., Cergentis B.V, Mdxhealth SA, NeoGenomics Laboratories Inc., Adaptive Biotechnologies, Thermo Fisher Scientific Inc., Siemens Healthineers AG, PerkinElmer Inc., Agilent Technologies Inc., ArcherDx Inc., Asuragen Inc., Becton Dickinson and Company, Cepheid Inc., Fluidigm Corporation, Illumina Inc., Invitae Corporation, Luminex Corporation, Menarini Silicon Biosystems S.p.A.
View The Full Minimal Residual Disease Testing Market Report:
Minimal Residual Disease Testing Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the minimal residual disease testing market in 2025. The regions covered in the minimal residual disease testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
